Background Worldwide, hepatocellular carcinoma (HCC) is a universal problem and its
epidemiological data showed variation from place to place. Hepatocellular carcinoma (HCC) …

Almost all patients with hepatocellular carcinoma (HCC), a major type of primary liver
cancer, also have liver cirrhosis, the severity of which hampers effective treatment for HCC …

Objective The benefit of direct-acting antivirals (DAAs) against HCV following successful
treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of …

An estimated 8–10 million people suffer from viral hepatitis in Egypt. Hepatitis A virus (HAV)
and hepatitis E virus (HEV) are the major causes of viral hepatitis in Egypt as 50% or more of …

Hepatocellular carcinoma (HCC) is the sixth most common primary malignancy worldwide,
and the third most common cause of death among cancers worldwide. HCC occurs in …

Background & Aims The effect of hepatocellular carcinoma (HCC) on the response to
interferon-free direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C (CHC) …

Background & Aims Despite direct-acting antivirals being highly effective at eradicating
hepatitis C virus infection, their impact on the development of hepatocellular carcinoma …

Hepatocellular carcinoma (HCC) is a disease of global public health significance with
mortality on the rise, despite the preventable nature of its risk factors especially in Africa. It is …

Hepatitis C virus (HCV) infection, defined by active carriage of HCV RNA, affects nearly
1.0% of the worldwide population. The main risk factors include unsafe injection drug use …

Viral hepatitis remains one of the largest public health concerns worldwide. Especially in
Central Africa, information on hepatitis virus infections has been limited, although the …